Signal Transduction
Stem Cells
Signaling Pathways
Product Type
All Products
New Products
Small Molecules
Peptides
Controlled Substances
Toxins
Caged Compounds
Fluorescent Probes
Screening Libraries
Ligand Sets
Other Product Types
Research Area
Cancer
Cardiovascular System
Endocrinology
Immunology
Neuroscience
Pain & Inflammation
Respiratory System
m-3M3FBSCat. No. 1941 |
Price and AvailabilityBy clicking submit you agree to accept a cookie from Tocris Bioscience. For details, please read our privacy and cookie policy. |
|
Chemical Name: 2,4,6-Trimethyl-N-[3-(trifluoromethyl)phenyl]benzenesulfonamide |
Biological Activity
Activator of phospholipase C (PLC). Stimulates superoxide generation, Ca2+ release and inositol phosphate formation in a variety of cell types. Also inhibits growth of the leukemic cell lines U937 and THP-1. Inactive control o-3M3FBS (Cat. No. 1942) available.Technical Data
M.Wt:The technical data provided above is for guidance only.
For batch specific data refer to the Certificate of Analysis.
Resources
Other Information
Certificate of Analysis / Safety Data Sheet
References
Bae et al (2003) Identification of a compound that directly stimulates phospholipase C activity. Mol.Pharmacol. 63 1043. PMID: 12695532.
Krjukova et al (2004) Phospholipase C activator m-3M3FBS affects Ca2+ homeostasis independently of phospholipase C activation. Br.J.Pharmacol. 143 3. PMID: 15302681.
Lee et al (2005) The novel phospholipase C activator, m-3M3FBS, induces monocytic leukemia cell apoptosis. Cancer Lett. 222 227. PMID: 15863272.
If you know of a relevant citation for this product please let us know.
View Related Products by Target
Keywords: m-3M3FBS, supplier, Phospholipases, C, activators, activates, PLC, esterases
Quick Order
Find multiple products by catalog number
Cancer Research Guide
Request your free copy
Highlights over 350 products for cancer research. Request a copy or view PDF today.
New Therapies and Challenges in Asthma
Written by Peter J. Barnes
'New Therapies, Challenges, and Breakthroughs in Asthma' highlights key pathways and new therapies used to treat asthma, including those currently in clinical development.
20% Discount*
Potent, selective LRRK2 inhibitor
Tocris is the first to launch GSK2578215A, licensed from GlaxoSmithKline, for the study of Parkinson's Disease.